Pharmaceutical giant Merck has announced that it will be filing a marketing approval with the US Food and Drug Administration next year for its experimental drug that reduces the allergic reactions to ragweed and grass.
Merck said that the results of its clinical trials revealed that those who took the drugs showed up to 27 percent reduction in the allergy symptoms. More than 560 adults between 18 and 50 years of age took part in the study with the participants given either two different doses of the drug or a placebo.
AdvertisementAccording to Merck, those who took a lower dose of the drug had 21 percent reduction in symptoms and 34 percent reduction in taking medication compared to the placebo group while those who took the higher dose had 27 percent reduction in symptoms and 45 percent reduction in medication.
You May Also Like